Navigation Links
New animal study shows promise for development of Parkinson's disease drug
Date:6/9/2011

Amsterdam, NL, 9 June 2011 Few treatments for Parkinson's disease (PD) restore function for extended periods. In a new study published today in the inaugural issue issue of the Journal of Parkinson's Disease, an international group of researchers report that platelet-derived growth factor-BB (PDGF-BB) restored function in rodents and shows promise as a clinical candidate drug for treatment of PD.

Parkinson's disease is the second most common neurodegenerative disorder, affecting 1𔃀% of the population over the age of 65. It is characterized by loss of brain cells (neurons) from the mid-brain which use the neurotransmitter dopamine to help control voluntary movements. Investigators from NeuroNova AB, Stockholm, Sweden, the Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden, The Parkinson's Institute, Sunnyvale, CA, USA, and Motac Neuroscience Ltd, Manchester, UK, found that behavioral, tissue and biochemical changes in experimental models of Parkinson's disease in rodents could be counteracted by infusion of PDGF-BB. This could offer an alternative strategy to restore function in PD.

"In animal models of nigrostriatal injury, a two weeks treatment with platelet-derived growth factor-BB resulted in long-lasting restoration of striatal dopamine transporter binding sites and expression of nigral tyrosine hydroxylase," commented Anders Haegerstrand, MD, PhD, Chief Scientific Officer, NeuroNova AB, Stockholm, Sweden."It also normalized amphetamine-induced rotational behavior in 6-hydroxydopamine lesioned rats. Platelet-derived growth factor-BB promoted proliferation of neural progenitor cells in the subventricular zone. The effects on dopaminergic neurons and functional recovery could be blocked by co-infusion with a proliferation inhibitor, indicating a link between the proliferative and anti-parkinsonian effects. Based on the current data, we consider platelet-derived growth factor-BB a clinical candidate drug for treatment of Parkinson's disease."


'/>"/>

Contact: Daphne Watrin
d.watrin@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Related medicine news :

1. Mammary gland development of blueberry-fed lab animals studied
2. Animal results may pave way to treating rare mitochondrial diseases in children
3. Study finds pigs susceptible to virulent ebolavirus can transmit the virus to other animals
4. Animal studies reveal new route to treating heart disease
5. Animal-assisted therapy decreases patient anxiety in pre-MRI setting, study suggests
6. Multiple Pregnancies May Up Risk of Obesity, Diabetes: Animal Study
7. New drug shrinks cancer in animals, U-M study shows
8. Animal Hoarding Often Tied to Mental Illness
9. Animal Study May Explain Low Birth Weight-Obesity Link
10. Speaker series highlights the role of animals in human culture
11. Researchers discover way to halt lung inflammation in animal models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Textile Exchange is excited to announce ... stakeholder review. The stakeholder review is an important opportunity for interested parties to give ... value to the wool industry., The RWS is intended to be a global benchmark ...
(Date:5/5/2016)... Diego, CA (PRWEB) , ... May 05, 2016 , ... ... dashboard and dedicated Twitter feed to cover the latest news and commentary at the ... through 10th. This meeting of the American Society of Cataract and Refractive Surgery and ...
(Date:5/5/2016)... ... 2016 , ... TLC Laser Eye Centers announced today that it has acquired ... now be called “Gordon Schanzlin New Vision Institute, a TLC Laser Eye Center.” ... to ensure that patients continue to receive the highest quality of care. In addition, ...
(Date:5/5/2016)... ... May 05, 2016 , ... Spring Fertility , ... IVF and with egg freezing, today announced the grand opening of its first ... fertility care, Spring Fertility offers both fertility preservation (egg, sperm, embryo, and testicular ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... Seminars for Business Journalists , led by the Wharton School’s most prominent ... issues.  This one-day program at the Wharton School’s San Francisco campus will ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... Global NASH market report ... rise in obesity will fuel the demand for ... years. The NASH Market is growing at a ... of rising number of obesity among young population. ... with no FDA approved therapeutics. Antioxidants, anti-diabetic medications, ...
(Date:5/5/2016)... , May 5, 2016  Replikins Ltd. today reported initial promising results in animal ... Photo - http://photos.prnewswire.com/prnh/20160505/364345 ... ... ... of all Zika specimens recorded on Pubmed. The analysis identified the highest gene Replikin ...
(Date:5/5/2016)... , May 5, 2016  Endo International ... today announced that Brian Lortie , President, ... from his position upon the appointment of a ... led its U.S. Pharmaceuticals business with responsibility for ... and marketing, strategy and portfolio development, commercial operations, ...
Breaking Medicine Technology: